Novartis Innovationspreis „Junior meets Senior“: vom innovativen Studienkonzept zur patientenintegrierten Versorgung

Nina Caroline Ditsch; Michael Untch

doi:10.1055/a-2128-1226

Senologie - Zeitschrift für Mammadiagnostik und -therapie, Inhaltsverzeichnis

Senologie - Zeitschrift für Mammadiagnostik und -therapie 2023; 20(03): 207-209
DOI: 10.1055/a-2128-1226

Aktuell diskutiert

Novartis Innovationspreis „Junior meets Senior“: vom innovativen Studienkonzept zur patientenintegrierten Versorgung

Nina Caroline Ditsch

,

Michael Untch

Abstract

Volltext

Referenzen

Literatur
1 Untch M, Ditsch N, Bauerfeind I. et al. Primäre Chemotherapie beim Mammakarzinom. In: Untch M, Sittek H, Bauerfeind I. Diagnostik und Therapie des Mammakarzinoms, State of the Art. München: Zuckschwerdt Verlag; 2002
2 Untch M, Kochecny G, Ditsch N. et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. J Clin Oncol 2002; 21: 133
3 Ditsch N, Vodermaier A, Hinke A. et al. Dose-dense Intensified Sequential Versus Conventionally-dosed Anthracycline and Taxane-containing Neoadjuvant Therapy in Patients with Inflammatory Breast Cancer. Anticancer Research 2012; 32: 3539-3545
4 Untch M, Fasching PA, Ditsch N. et al. Pathological complete response after neoadjuvant chemotherapy plus trastuzumab predicts favourable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study group. J Clin Oncol 2011; 29: 3351-3357
5 Rückert S, Mosner M, Ditsch N. et al. Die TECHNO-Studie (Taxol-Epirubicin-Cyclophosphamid-Herceptin-neoadjuvant) ein herceptinhaltiges präoperatives Studienkonzept der AGO. Arch Gynecol and Obstet 2004 (55. Kongress der DGGG 2004): PO-27.4.
6 Cortazar P, Zhang L, Untch M. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-172
7 Marme F, Hanusch C, Furlanetto J. et al. Safety interim analysis of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan in patients with primary HER2-negative breast cancer at high relapse risk after neoadjuvant treatment. Deutscher Krebskongress 2022, Poster #504.
8 von Minckwitz G, Huang CSe, Mano MS. et al. KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380: 617-628
9 Geyer C, Untch M, Prat A. et al. Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual, invasive,early breast cancer after neoadjuvant therapy: a randomized phase 3 trial (DESTINY-Breast05). SABCS 2021, Poster.
10 Marmé F, Solbach C, Michel L. et al. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2021; 153: 203-212
11 Tutt ANJ, Garber JE, Kaufman B. et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med 2021; 384: 2394-2405
12 Ditsch N, Kahlert S, Lenhard M. et al. Immunologische Therapie beim Mammakarzinom. Der Onkologe 2006; 12: 944-954
13 Ditsch N, Untch M, Wiegrebe W. et al. Bessere Erfolge durch individualisierte Chemotherapie. Pharm Ztg 2003; 148: 14-24
14 Schmid P, Cortes J, Pusztai L. et al. KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020; 382: 810-821
15 Kuehn T, Bembenek A, Decker T. et al. Consensus Committee of the German Society of Senology. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer 2005; 103: 451-461
16 Kuehn T, Bauerfeind I, Fehm T. et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013; 14: 609-618
17 Schwentner L, Helms G, Nekljudova V. et al. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy – Results from the multi-center SENTINA trial. Breast 2017; 31: 202-207
18 Pochert N, Schneider M, Ansorge N. et al. Seroma after Simple Mastectomy in Breast Cancer-The Role of CD4+ T Helper Cells and the Evidence as a Possible Specific Immune Process. Int J Mol Sci 2022; 23: 4848
19 Pochert N, Schneider M, Köpke MB. et al. Th2/Th17 cell associated cytokines found in seroma fluids after breast cancer surgery. Arch Gynecol Obstet 2023;
20 Köpke MB, Wild CM, Schneider M. et al. Elderly and Patients with Large Breast Volume Have an Increased Risk of Seroma Formation after Mastectomy-Results of the SerMa Pilot Study. Cancers (Basel) 2023; 15: 3606